Searched for
EMCURE PHARMA SHARE PRICE
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brok...- Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 croreEmcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substan...
- Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 croreEmcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore....
- Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanzaAs per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be ...
- Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun PharmaIndian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC face...
- High Court restrains NPPA from action against AstraZenecaThe Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in e...
- Market Trading Guide: Tata Steel among 5 stocks to buy on Tuesday for healthy returnsIndian equities experienced a strong start to the week, bolstered by better than expected Q2 earnings. Improved domestic macro indicators c...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugsOver the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth ...
- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- Time to be be cautious in the market, convinced about the business: 5 large-cap stocks with upside potential of up to 22%This is the time to focus on businesses that have lived through storms like this before and come out the other side. The large, proven name...
- Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred ac...
- For investors with ability to look past the current bearish narrative: 5 large-cap stocks with upside potential of up to 34%One stock not falling on bad news does not mean the worst is over for the whole market. It may mean only that the bears have, for now, take...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian markets closed lower on Wednesday as rising crude oil prices and Middle East tensions hurt sentiment. Sensex fell 353 points to 73,2...
- Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a lookIn response to recent market fluctuations, Kotak Institutional Equities has revamped its model portfolio, strategically introducing five mi...
- D-Street in gloomy mood, but Kotak sees 3 triggers for rebounds and adds 5 midcap stocks to portfolioDalal Street faces significant market challenges, leading Kotak Institutional Equities to spotlight selective stock value. With large-cap s...
- Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 croreMankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, s...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
Load More
